MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Deferred Revenue 2011-2026 | SNOA
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 641 K | 478 K | 160 K | 1.22 M | 267 K | 273 K | 102 K | 206 K | 521 K | 574 K | 769 K | 2.63 M | 2.32 M | 1.62 M | 1.81 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.63 M | 102 K | 906 K |
Quarterly Deferred Revenue Sonoma Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 314 K | 750 K | 731 K | 641 K | 302 K | 319 K | 413 K | 478 K | 75 K | 101 K | 100 K | 100 K | 100 K | 100 K | 100 K | 1.22 M | 100 K | 100 K | 185 K | 267 K | 150 K | 150 K | 150 K | 150 K | 228 K | 228 K | 228 K | 47 K | 174 K | 186 K | 139 K | 147 K | 180 K | 199 K | 285 K | 345 K | 794 K | 651 K | 656 K | 274 K | 456 K | 391 K | 507 K | 769 K | 1.56 M | 1.99 M | 2.25 M | 2.63 M | 2.66 M | 2.32 M | 2.28 M | 2.32 M | 2.87 M | 2.87 M | 1.63 M | 1.62 M | 1.85 M | 1.9 M | 1.88 M | 1.81 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.87 M | 47 K | 807 K |
Deferred Revenue of other stocks in the Drug manufacturers industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
85.4 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
49 K | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
250 M | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
27.8 K | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
545 K | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
600 K | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
788 K | $ 38.95 | -27.32 % | $ 1.43 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
114 K | - | - | $ 2.06 B |  France |
 |
China Pharma Holdings
CPHI
|
162 K | $ 0.55 | -0.97 % | $ 9.61 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
207 K | $ 4.5 | -7.02 % | $ 63.3 M | USA |
 |
HEXO Corp.
HEXO
|
8.21 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Aurora Cannabis
ACB
|
27 M | $ 3.52 | -5.26 % | $ 86.3 M | Canada |
 |
Athenex
ATNX
|
2.82 M | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
27.2 M | $ 8.87 | -1.33 % | $ 454 M | USA |
 |
ProPhase Labs
PRPH
|
2.5 M | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
200 K | $ 11.92 | 1.24 % | $ 847 M | USA |
 |
Radius Health
RDUS
|
1 M | - | - | $ 1.42 B | USA |
 |
Rockwell Medical
RMTI
|
46 K | $ 0.9 | 0.37 % | $ 21 M | USA |
 |
Evolus
EOLS
|
11.5 M | $ 4.21 | -1.86 % | $ 261 M | USA |
 |
Bausch Health Companies
BHC
|
26 M | $ 5.77 | -3.11 % | $ 2.11 B | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Perrigo Company plc
PRGO
|
122 M | $ 11.38 | -7.97 % | $ 1.58 B | USA |
 |
Pacira BioSciences
PCRX
|
102 K | $ 22.06 | 3.67 % | $ 1.02 B | USA |
 |
OptiNose
OPTN
|
160 K | - | - | $ 1.08 B | USA |
 |
Recro Pharma
REPH
|
543 K | - | -4.76 % | $ 65.3 M | USA |
 |
SCYNEXIS
SCYX
|
1.19 M | $ 0.73 | -2.19 % | $ 34.9 M | USA |
 |
Solid Biosciences
SLDB
|
10.4 M | $ 5.99 | -3.47 % | $ 244 M | USA |
 |
TherapeuticsMD
TXMD
|
523 K | $ 2.26 | 1.0 % | $ 23.6 M | USA |
 |
Tilray
TLRY
|
23.7 M | $ 7.37 | -2.97 % | $ 4.55 B | Canada |
 |
Veru
VERU
|
400 K | $ 2.54 | -3.05 % | $ 343 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
172 K | - | - | $ 55.5 M | USA |
 |
cbdMD
YCBD
|
503 K | $ 0.79 | -2.48 % | $ 3.41 M | USA |